Elyxium Wealth LLC Sells 22,468 Shares of Pfizer Inc. (NYSE:PFE)

Elyxium Wealth LLC cut its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 65.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 12,102 shares of the biopharmaceutical company's stock after selling 22,468 shares during the quarter. Elyxium Wealth LLC's holdings in Pfizer were worth $321,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer during the fourth quarter worth about $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer during the 4th quarter worth about $27,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $28,000. Finally, Noble Wealth Management PBC acquired a new position in shares of Pfizer during the 4th quarter worth about $31,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 3.6%

NYSE PFE traded up $0.81 on Monday, reaching $23.09. The company had a trading volume of 77,353,772 shares, compared to its average volume of 40,671,777. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company's fifty day moving average is $24.02 and its 200 day moving average is $25.52. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The stock has a market capitalization of $131.25 billion, a P/E ratio of 16.37, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period last year, the company posted $0.82 earnings per share. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.45%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent analyst reports. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.